Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  human papillomavirus vaccine V503
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
Phase: Phase III
Type: Prevention
Status: Closed
Age: 16 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V503-001, 2007_538, NCT00543543
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Phase: Phase III
Type: Prevention
Status: Closed
Age: 9 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V503-002, 2009_611, NCT00943722
A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)
Phase: Phase III
Type: Prevention
Status: Completed
Age: 11 to 15
Sponsor: Pharmaceutical / Industry
Protocol IDs: V503-005, NCT00988884
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
Phase: Phase III
Type: Prevention
Status: Closed
Age: 12 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V503-006, 2010_504, NCT01047345
A Study of the Safety, Tolerability, and Immunogenicity of a 9-valent Human Papillomavirus Vaccine ([9vHPV]; V503) Administered to 9- to 15-Year-Old Japanese Girls (V503-008).
Phase: Phase III
Type: Prevention
Status: Completed
Age: 9 to 15
Sponsor: Pharmaceutical / Industry
Protocol IDs: V503-008, NCT01254643
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Phase: Phase III
Type: Prevention
Status: Completed
Age: 16 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V503-003, 2012-002758-22, NCT01651949
A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 9 to 14 and 16-26
Sponsor: Pharmaceutical / Industry
Protocol IDs: V503-010, 2013-001314-15, NCT01984697
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men
Phase: Phase III
Type: Prevention
Status: Closed
Age: 16 to 26
Sponsor: Pharmaceutical / Industry
Protocol IDs: GDS07C, 2013-003399-10, V503-020, NCT02114385
Start Over